Covid-19 pandemic: Can Moderna buy its way into the $200 billion club?

Moderna Inc.'s highly effective Covid vaccine, in addition to protecting millions, is officially a cash cow. The company disclosed during its earnings presentation Aug. 5 that it expects the shot to generate $20 billion in sales this year. Now it has to figure out what to do with its windfall as it tries to justify a market valuation that has surged by more than $100 billion since May. That's a nice problem to have. But it's also an urgent strategic issue.
 

The Cambridge, Massachusetts-based biotechnology firm’s astonishing stock surge has been driven by the success of its vaccine and excitement